{"ticker": {"uuid": "80a42afd-4921-4949-bca7-94f7857f8c22", "symbol": "MYGN", "name": "Myriad Genetics Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Diagnostics & Research"}, "articles": [{"title": "Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Myriad Genetics Inc (MYGN) stock, focusing on its historical dividend payouts and stock split events. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mygn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:28", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Myriad Genetics Inc (MYGN) as of April 6, covering analysis by business segment and geographical region. The company's main revenue streams are Hereditary Cancer, Prenatal, Pharmacogenomics, and Tumor Profiling, with Heredita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mygn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:28", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc (MYGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Myriad Genetics Inc (MYGN), highlighting its current earnings forecast score of 5.82, ranking it 184 out of 203 in its industry. Analysts have set an average price target of $8.00 for MY", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mygn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T02:09:43", "published_display": "17 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc (MYGN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Myriad Genetics Inc (MYGN) as of June 16, 2026. The company's valuation score is 8.29, ranking it 98th in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.99, which is noted as being below its recent high and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mygn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-15T09:09:43", "published_display": "15 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan", "summary": "Myriad Genetics CEO Samraat S. Raha acquired 3,542 shares of common stock on June 11, 2026, through the company's Amended and Restated 2012 Employee Stock Purchase Plan at $3.936 per share. This transaction increases his direct holdings to 1,068,083 shares and is considered a rou", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-aecf7cb0b269.html", "source_name": "Stock Titan", "published_at": "2026-06-12T22:10:26", "published_display": "12 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan", "summary": "Myriad Genetics Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of common stock through the company's Employee Stock Purchase Plan at $3.936 per share. This transaction, exempt under Rule 16b-3(d) and Rule 16b-3(c), increased his direct holdings to 573,363 shares", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-96b15f3859dc.html", "source_name": "Stock Titan", "published_at": "2026-06-12T22:10:26", "published_display": "12 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Add Myriad Genetics Stock to Your Portfolio Right Now?", "summary": "Myriad Genetics (MYGN) is positioned for growth due to new product launches, particularly in oncology testing, and a sound solvency profile, despite foreign exchange headwinds. The company's focus on germline and tumor testing, alongside FDA approvals and upcoming AI-enhanced tes", "url": "https://ca.finance.yahoo.com/news/add-myriad-genetics-stock-portfolio-140100237.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-12T22:09:27", "published_display": "12 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of \"Hold\" from Analysts", "summary": "Myriad Genetics (NASDAQ:MYGN) has received an average \"Hold\" rating from six analysts, with a consensus 12-month price target of $6.50. The company recently reported quarterly earnings that missed estimates, with an EPS of -$0.09 and revenue of $200.4 million, despite a 2.3% year", "url": "https://www.marketbeat.com/instant-alerts/myriad-genetics-inc-nasdaqmygn-receives-average-rating-of-hold-from-analysts-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T19:09:18", "published_display": "10 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan", "summary": "Myriad Genetics Inc. director Rashmi Kumar sold 15,000 shares of common stock on June 8, 2026, at a weighted average price of $4.4562 per share, totaling $66,843. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Kumar directly owns ", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-4748c5e452c7.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:10:14", "published_display": "09 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] MYRIAD GENETICS INC SEC Filing", "summary": "This SEC filing details a Form 144 Notice of Proposed Sale of Securities for MYRIAD GENETICS INC (MYGN). The filing indicates an intent to sell 15,000 shares of common stock with an aggregate market value of $68,850.00, acquired via restricted stock vesting. The proposed sale dat", "url": "https://www.stocktitan.net/sec-filings/MYGN/144-myriad-genetics-inc-sec-filing-f171c50115cc.html", "source_name": "Stock Titan", "published_at": "2026-06-08T15:39:09", "published_display": "08 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis", "summary": "Myriad Genetics (MYGN) director Mark Steven Davis was granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan, bringing his total direct holdings to 106,665 common shares. These RSUs were granted at no purchase price and will vest on the e", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-677fa42f2436.html", "source_name": "Stock Titan", "published_at": "2026-06-06T05:10:17", "published_display": "06 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) director awarded 59,701 restricted stock units", "summary": "Myriad Genetics (MYGN) director Lee Nisley Newcomer was granted 59,701 restricted stock units, as reported in a recent Form 4 SEC filing. These units, awarded at no purchase price under the company\u2019s 2026 Equity Incentive Plan, will vest upon the earlier of the first anniversary ", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-0cdc6878e6d7.html", "source_name": "Stock Titan", "published_at": "2026-06-06T04:40:08", "published_display": "06 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ: MYGN) director receives 59,701 restricted stock units", "summary": "Myriad Genetics director Colleen F. Reitan was granted 59,701 restricted stock units (RSUs) under the company's 2026 Employee, Director and Consultant Equity Incentive Plan. This equity award, which is compensation-related rather than a stock purchase, increases her direct holdin", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-b05faa181c6f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] MYRIAD GENETICS INC Insider Trading Activity", "summary": "Myriad Genetics Inc. director S. Louise Phanstiel was granted 59,701 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan at no cash cost. These RSUs will vest upon the earlier of one year from the grant date or the next annual stockholders' meeting. Follo", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-cc3015b716f9.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ: MYGN) director granted 59,701 restricted stock units in equity award", "summary": "Myriad Genetics (NASDAQ: MYGN) director Rashmi Kumar was granted 59,701 restricted stock units (RSUs) as an equity award, bringing her direct holdings to 186,889 shares. These RSUs were granted at no cash cost under the company's 2026 Employee, Director and Consultant Equity Ince", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-16aaf12385bf.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant", "summary": "Myriad Genetics (MYGN) Director Heinrich Dreismann was granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan. These RSUs, awarded at no cash cost, will vest upon the earlier of one year from the grant date or the next annual stockholder ", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-f30e2e25ed96.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro", "summary": "Myriad Genetics (MYGN) director Paul Bisaro has been granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Employee, Director and Consultant Equity Incentive Plan. These RSUs, which have no purchase price, will vest on the earlier of one year from the grant d", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-93bd8c439873.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?", "summary": "Myriad Genetics (MYGN) shares have risen 7.1% since its last earnings report, outperforming the S&P 500. Despite missing Q1 earnings estimates with an adjusted loss of 9 cents per share and a revenue miss, the company's Cancer Care Continuum and Mental Health businesses showed gr", "url": "https://finance.yahoo.com/markets/stocks/articles/myriad-mygn-7-1-since-153022589.html", "source_name": "Market source", "published_at": "2026-06-05T04:38:43", "published_display": "05 Jun 2026 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ: MYGN) shareholders approve 2026 equity and purchase plans", "summary": "Myriad Genetics (NASDAQ: MYGN) held its 2026 Annual Meeting of Stockholders, where shareholders approved significant expansions to the company's equity and stock purchase plans. This included an amendment to the 2012 Employee Stock Purchase Plan adding 4,000,000 shares and the ad", "url": "https://www.stocktitan.net/sec-filings/MYGN/8-k-myriad-genetics-inc-reports-material-event-19b6b7126a6f.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:09:12", "published_display": "04 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc Annual Shareholders Meeting Transcript", "summary": "This article provides the transcript for the 2026 Annual Shareholders Meeting of Myriad Genetics Inc. The meeting was called to order by Independent Chairman of the Board, S. Louise Phanstiel, at 8:00 AM Mountain Time, and an agenda for the meeting was made available on the compa", "url": "https://www.gurufocus.com/stock/MYGN/transcripts/8901765", "source_name": "GuruFocus", "published_at": "2026-06-04T14:09:12", "published_display": "04 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Names Raj Jampa as New Chief Technology Officer", "summary": "Myriad Genetics, a leader in molecular diagnostic testing, has appointed Raj Jampa as its new Chief Technology Officer, effective June 1, 2026. Jampa will be responsible for technology strategy and execution, focusing on leveraging AI to enhance efficiency and customer experience", "url": "https://www.globenewswire.com/news-release/2026/06/02/3305286/0/en/myriad-genetics-names-raj-jampa-as-new-chief-technology-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T04:09:12", "published_display": "03 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) CTO Raj Jampa receives 251,889 restricted stock units", "summary": "Myriad Genetics' CTO, Raj Jampa, has been granted 251,889 restricted stock units (RSUs) as part of an equity compensation package. This award, which has no cash purchase price, vests in four equal annual installments starting one year from the grant date, aligning his compensatio", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-f27fef54494f.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:10:32", "published_display": "02 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) CTO Raj Jampa files initial Form 3 insider report", "summary": "Raj Jampa, Chief Technology Officer of Myriad Genetics (MYGN), has filed an initial Form 3 insider report. This filing establishes him as an insider for future reporting purposes but does not record any stock or option transactions, indicating a neutral impact on the company's st", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-3-myriad-genetics-inc-initial-statement-of-beneficial-ownership-12cc8eb61922.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:10:32", "published_display": "02 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Myriad Genetics Names Raj Jampa as New Chief Technology Officer", "summary": "Myriad Genetics has announced the appointment of Raj Jampa as its new Chief Technology Officer (CTO). Jampa will be responsible for leading the company's technology strategy, including software development and bioinformatics infrastructure. This strategic hire aims to enhance Myr", "url": "https://www.moomoo.com/news/post/70934425/press-release-myriad-genetics-names-raj-jampa-as-new-chief?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-02T15:10:32", "published_display": "02 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics names Raj Jampa as chief technology officer", "summary": "Myriad Genetics, Inc. has appointed Raj Jampa as its new chief technology officer, effective Monday. Jampa will be responsible for leading the company's technology strategy, modernizing infrastructure, and scaling AI capabilities. His appointment is expected to help the molecular", "url": "https://www.investing.com/news/company-news/myriad-genetics-names-raj-jampa-as-chief-technology-officer-93CH-4722177", "source_name": "Investing.com", "published_at": "2026-06-02T13:40:19", "published_display": "02 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New CTO Raj Jampa to modernize tech and AI at Myriad Genetics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQRFVhdDVqSDlLYndNbEpPMm5OQ05EbURhTmNiZHFEUklmZW1TX2pPX2EySHM1OFUwYXpSRkJyT2J5QThTVW1SbmdrbXVxNzZ0bEJHNVU4RFBfQkFMT0FSTnp4Qjl1cjM2bDFtWlpjMnNBZUpGZkoyVndyOFl2aW51dHVPSXMyNWFVZEd5SmZKdjBoOF9qRUN6UUJXMVZ2TnowU2xfckRIdmppZ0MxY2dV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics, Inc. (MYGN) News, Articles, Events & Latest Updates", "summary": "This page provides the latest news and updates for Myriad Genetics, Inc. (MYGN), including stock performance, financial fundamentals, and recent articles. Key topics covered include the company's Q1 2026 earnings, upcoming product launches like the Prolaris + AI Test, analyst rat", "url": "https://stocktwits.com/symbol/MYGN/news", "source_name": "Stocktwits", "published_at": "2026-05-29T15:10:32", "published_display": "29 May 2026 15:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/myriad-genetics-upcoming-prolaris-ai-132400644.html", "source_name": "Zacks", "published_at": "2026-05-28T13:24:00+00:00", "published_display": "28 May 2026 13:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPdFJpT2xJbnl6UlQ4aUNrS25wT2t0OVZ6Zm1XREI1TzNqcGtMUTVOYTFkSTFpVzlSdTd1RWlScnlsV1pYNTFRdEcwZF8tMXRaaGRndVlFQUk4YmQ3cUdqc2VOeC1lQ0tfLTNNeXlGRmlldjRiM196U0I5dUt2aUNTbnV1ZFFjMjVHVkE?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics stock (US62855J1043): Q1 2026 earnings miss and recent price drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQUEVjRGlnUk40NUZ4UmtudTY4TFVEXzAtWnFLa2V3UVJaUUEtMnBfWXFjV3VBUnkydUIyb1dMOUxZa3pNb18wdWJ5NGxLUk9lQ1pLOVluYXo2eUtIWlFPeUVUZzNsdWt3QS1fTFJOdF9WMHQ3dC1rZDJFNU1sODJZMXBNVTFtMnB2QjhJb2ZfMHZBa0ZwQW92dS04dm0tLUJlWkJwc05tQXQ5b0o2TnQ2Sm0yRWQwdS1FblBLSjMxeU1nb3BD?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPaWVwVVoxQnYxSGFFNVRCTlZGaW85N2FKQjRJd3ZnLTQwU0ttbXJPWjJVc3Y5OFJKOFVoUXdVakoyckpPWlljd3RYUkx2M2h5WWJRZ2hGTWRSTmZ0QjM2U2lsYVo2eDRYN3BBYXZnQ0xRVzZyVEVqN1YyQTJxeG9jRGtLdFlYYmk3RXdMeW1EUFNiMXlvbW15clpSX3BTS1Iw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics in record sell-off after Q1 miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOMXpsS2ZOdDc5RXhJMWxndWU2bk5YR1ZSQXc1dHowOVczR1g3eG4zS1RhU1ZVTlM4eHNNUTREbFJEbnVLTnRQV1NjNWtmQ3dMbmlHS1RxeS1kNEE4eDlVYk1rUHRKNGJCMm9lc1lvWFZqRnNucW90aTBsT1hhTW5fR0RRM3NKbVl6b1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) Q1 Loss Of US$34.1 Million Reinforces Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNa0R1d05KZE1qVlBnU2RQNUpRQUp4V0xibE13LTgwbkxsb052WXdyVV9US0FVTGxFdDdYaENMNVJpbHotX1diLXVIOG05VktyQnBHdXNJVkRzbVlyUHJJWnVNNkpfcERrNDBmZW4yTG80SG85TFlrV3piUDVfV1QtUW1LQnZEc0h3Nm5KRUNsT2VuYkZleE5lU181NFBpZ0dP?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOUS1GdEV4WGdwdnFwZ3lZdmZLTnlDMDJqb1hjLWRVdlg5dk0wTzgzWDZfVm9wNnVQU190MVh1RnFFRVVqdTFqdDNsYjYtdGpVYk9BY0tYcEJ3a0RVYkljSmFER240THdKaC1uVkZ3NUh1bkFZZUxhUmdRUk96dzYzRllIMnluWjBrWUVxV19teWQyV2VGaE1xOURpdXo?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Small-Cap Stocks: Krispy Kreme, Myriad Genetics, and Hamilton Insurance Group to Avoid - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE9Damt6QjMzN2ZhYnBJS0JxU0ZzSGI1LXAwMmZ2aHo4T1pPbjBQZlZNdHVZX3BCZTBLOFdmek8xa3VkQnJVb3BVeHhrcEtEN09sdWYzUUZSSlRBVzhHSGlDQWtMSUlrSmdHdXhQXzF5bE1rSG8?oc=5", "source_name": "IndexBox", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Q4 2025 Results: Revenue Beat, Raised Guidance - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOZzIyb0FCSGZNT1RzRnh4NG9LRzNWcFJoX0VwUE9OQkI5eE5BcVBlOGpSaUdic3hYd2ZzcWVSSVluamxhYzBXTC1NZGJkMHJhQUJMNDliTXc3QWplNjQyZngwXzNHUzFnZ2JncTRXOUw3Q0xvUVREbHdnVWlfOW5yN2RnaUxfWTBGTWRMdjE2R243allNWW1ISGJKd2M2c01YQWNv?oc=5", "source_name": "IndexBox", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics And 2 Other Penny Stocks To Watch Closely", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOTXNRMVpadDRYNDBTdHFQMDJYQkZDMGZ0NVNWX1h3N3JNR3Nnc3UxT202dmdyVGZKNlluV05ja2QxSmttTVVuUVA3SWtWNkNWZlZuNC1oVzlGWGxtVlAzcDZsdVhQUmxzZ2FFc0FIT19GMk9NMWFpS1hnR3YtWTZvb090WlNXZ2YxUW5XQUpWN0VZbU5RdFFXOVZ3?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) Stock Trades Up, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNUXM4OFZEczV5ZHNlc1pEN0lJNGlDa1F4NjN0MWFydWFvcU9GQ2R5WXQzRjRPaV9pRFh6WnNyX05lVHdETlE4VXAzSy01TEg4U3gwWERaQTRaR1ctd2ZUb1hSQ2hzbElQYVQyNjBISTVJeFI3cVVxSUJ0REF4bzZDQ3h3c2cydw?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOZE5GNWRZUERzNlEzZkN1WERnMWk5VTkwS1NGTWxYV2JXWW84QlJXWlpndkw4SzVrMjktVVpWYm52LUlNV1dPWjRuak0wUXJJcWxmVUkzZFE0b04xXzd1LUZHRnVKak9vRFRBbkZfUjBIS205X3JzZF9kNHFfQjRfTHBGMnBHWW5LTUtYaHdPVGZmMzNTb1E?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Analysts See The Myriad Genetics (MYGN) Story Shifting After The New $7 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPMFMwTmN3VkxnZW9KOHZwSEtlaXhWYmxiSUVQUFVyWHhnOFI2RHU1Tkh6SC1qaFZDanZtMUVaRl8wbHdKdG1DYlpxS3N5ajdPS1AydXUwbEdtcFhOcmlNNGJ0QWNQdURiQmozeFdtcUdra1ZMd2h6dFFDcDRlNVR1NS1fYTg?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQZktGM0tUVjlYN3pQczJDS29wREgxWTRnQ1daT2xoN2ZPOFI0VDZsTEo3LUVINi0zaXlOR25OM0pQOHh4Nk1jNjY1dDQzUVNMX0d0a21IVnhINDFMV2NLRnEyWjFST0x1TTRndWpDQ0l6ZVVfZ2VycWlYTjJIUV94dzFQSV9oUHMtSDd2eGt2SEY5M3VM?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Myriad Genetics (MYGN) Stock Is Down Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNdFR3YkJLaEFsM3JuQmFKR0ExN09BTUdwWml5ZWxBdU5yV3lIVTk4RG5vYjlzVnFsdlItTUdhSzZaeUJjUElKMXktV1ZKNGs0a0I5LUhzLW9MSHhYWkwxUGczcWFESkt3azU2bmZ3NGswU19aN3laTDh1cllHVmVnaG1n?oc=5", "source_name": "Market source", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of Myriad Genetics Inc (MYGN) stock, focusing on its historical dividend payouts and stock split events. It indicates that the company has not distributed any dividends over the past five years and has no recorded stock split data. The page also ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mygn/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:28", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc (MYGN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Myriad Genetics Inc (MYGN) as of April 6, covering analysis by business segment and geographical region. The company's main revenue streams are Hereditary Cancer, Prenatal, Pharmacogenomics, and Tumor Profiling, with Heredita", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mygn/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T21:11:28", "published_display": "17 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc (MYGN) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for Myriad Genetics Inc (MYGN), highlighting its current earnings forecast score of 5.82, ranking it 184 out of 203 in its industry. Analysts have set an average price target of $8.00 for MY", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mygn/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T02:09:43", "published_display": "17 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 59, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc (MYGN) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis of Myriad Genetics Inc (MYGN) as of June 16, 2026. The company's valuation score is 8.29, ranking it 98th in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.99, which is noted as being below its recent high and ", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-mygn/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-15T09:09:43", "published_display": "15 Jun 2026 09:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ: MYGN) CEO adds 3,542 shares via employee stock purchase plan", "summary": "Myriad Genetics CEO Samraat S. Raha acquired 3,542 shares of common stock on June 11, 2026, through the company's Amended and Restated 2012 Employee Stock Purchase Plan at $3.936 per share. This transaction increases his direct holdings to 1,068,083 shares and is considered a rou", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-aecf7cb0b269.html", "source_name": "Stock Titan", "published_at": "2026-06-12T22:10:26", "published_display": "12 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Executive at Myriad Genetics (MYGN) adds 5,000 shares via ESPP plan", "summary": "Myriad Genetics Chief Commercial Officer Brian J. Donnelly acquired 5,000 shares of common stock through the company's Employee Stock Purchase Plan at $3.936 per share. This transaction, exempt under Rule 16b-3(d) and Rule 16b-3(c), increased his direct holdings to 573,363 shares", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-96b15f3859dc.html", "source_name": "Stock Titan", "published_at": "2026-06-12T22:10:26", "published_display": "12 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should You Add Myriad Genetics Stock to Your Portfolio Right Now?", "summary": "Myriad Genetics (MYGN) is positioned for growth due to new product launches, particularly in oncology testing, and a sound solvency profile, despite foreign exchange headwinds. The company's focus on germline and tumor testing, alongside FDA approvals and upcoming AI-enhanced tes", "url": "https://ca.finance.yahoo.com/news/add-myriad-genetics-stock-portfolio-140100237.html", "source_name": "Yahoo! Finance Canada", "published_at": "2026-06-12T22:09:27", "published_display": "12 Jun 2026 22:09", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics, Inc. (NASDAQ:MYGN) Receives Average Rating of \"Hold\" from Analysts", "summary": "Myriad Genetics (NASDAQ:MYGN) has received an average \"Hold\" rating from six analysts, with a consensus 12-month price target of $6.50. The company recently reported quarterly earnings that missed estimates, with an EPS of -$0.09 and revenue of $200.4 million, despite a 2.3% year", "url": "https://www.marketbeat.com/instant-alerts/myriad-genetics-inc-nasdaqmygn-receives-average-rating-of-hold-from-analysts-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T19:09:18", "published_display": "10 Jun 2026 19:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) director sells 15,000 shares under 10b5-1 plan", "summary": "Myriad Genetics Inc. director Rashmi Kumar sold 15,000 shares of common stock on June 8, 2026, at a weighted average price of $4.4562 per share, totaling $66,843. This transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Following the sale, Kumar directly owns ", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-4748c5e452c7.html", "source_name": "Stock Titan", "published_at": "2026-06-09T20:10:14", "published_display": "09 Jun 2026 20:10", "sentiment": "negative", "sentiment_pct": 36, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] MYRIAD GENETICS INC SEC Filing", "summary": "This SEC filing details a Form 144 Notice of Proposed Sale of Securities for MYRIAD GENETICS INC (MYGN). The filing indicates an intent to sell 15,000 shares of common stock with an aggregate market value of $68,850.00, acquired via restricted stock vesting. The proposed sale dat", "url": "https://www.stocktitan.net/sec-filings/MYGN/144-myriad-genetics-inc-sec-filing-f171c50115cc.html", "source_name": "Stock Titan", "published_at": "2026-06-08T15:39:09", "published_display": "08 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) grants 59,701 RSUs to director Mark Davis", "summary": "Myriad Genetics (MYGN) director Mark Steven Davis was granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan, bringing his total direct holdings to 106,665 common shares. These RSUs were granted at no purchase price and will vest on the e", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-677fa42f2436.html", "source_name": "Stock Titan", "published_at": "2026-06-06T05:10:17", "published_display": "06 Jun 2026 05:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) director awarded 59,701 restricted stock units", "summary": "Myriad Genetics (MYGN) director Lee Nisley Newcomer was granted 59,701 restricted stock units, as reported in a recent Form 4 SEC filing. These units, awarded at no purchase price under the company\u2019s 2026 Equity Incentive Plan, will vest upon the earlier of the first anniversary ", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-0cdc6878e6d7.html", "source_name": "Stock Titan", "published_at": "2026-06-06T04:40:08", "published_display": "06 Jun 2026 04:40", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ: MYGN) director receives 59,701 restricted stock units", "summary": "Myriad Genetics director Colleen F. Reitan was granted 59,701 restricted stock units (RSUs) under the company's 2026 Employee, Director and Consultant Equity Incentive Plan. This equity award, which is compensation-related rather than a stock purchase, increases her direct holdin", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-b05faa181c6f.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[Form 4] MYRIAD GENETICS INC Insider Trading Activity", "summary": "Myriad Genetics Inc. director S. Louise Phanstiel was granted 59,701 restricted stock units (RSUs) under the company's 2026 Equity Incentive Plan at no cash cost. These RSUs will vest upon the earlier of one year from the grant date or the next annual stockholders' meeting. Follo", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-cc3015b716f9.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ: MYGN) director granted 59,701 restricted stock units in equity award", "summary": "Myriad Genetics (NASDAQ: MYGN) director Rashmi Kumar was granted 59,701 restricted stock units (RSUs) as an equity award, bringing her direct holdings to 186,889 shares. These RSUs were granted at no cash cost under the company's 2026 Employee, Director and Consultant Equity Ince", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-16aaf12385bf.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) director receives 59,701 restricted stock units in equity grant", "summary": "Myriad Genetics (MYGN) Director Heinrich Dreismann was granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Equity Incentive Plan. These RSUs, awarded at no cash cost, will vest upon the earlier of one year from the grant date or the next annual stockholder ", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-f30e2e25ed96.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) grants 59,701 RSUs to board director Bisaro", "summary": "Myriad Genetics (MYGN) director Paul Bisaro has been granted 59,701 restricted stock units (RSUs) as part of the company's 2026 Employee, Director and Consultant Equity Incentive Plan. These RSUs, which have no purchase price, will vest on the earlier of one year from the grant d", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-93bd8c439873.html", "source_name": "Stock Titan", "published_at": "2026-06-05T20:38:43", "published_display": "05 Jun 2026 20:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad (MYGN) Up 7.1% Since Last Earnings Report: Can It Continue?", "summary": "Myriad Genetics (MYGN) shares have risen 7.1% since its last earnings report, outperforming the S&P 500. Despite missing Q1 earnings estimates with an adjusted loss of 9 cents per share and a revenue miss, the company's Cancer Care Continuum and Mental Health businesses showed gr", "url": "https://finance.yahoo.com/markets/stocks/articles/myriad-mygn-7-1-since-153022589.html", "source_name": "Market source", "published_at": "2026-06-05T04:38:43", "published_display": "05 Jun 2026 04:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ: MYGN) shareholders approve 2026 equity and purchase plans", "summary": "Myriad Genetics (NASDAQ: MYGN) held its 2026 Annual Meeting of Stockholders, where shareholders approved significant expansions to the company's equity and stock purchase plans. This included an amendment to the 2012 Employee Stock Purchase Plan adding 4,000,000 shares and the ad", "url": "https://www.stocktitan.net/sec-filings/MYGN/8-k-myriad-genetics-inc-reports-material-event-19b6b7126a6f.html", "source_name": "Stock Titan", "published_at": "2026-06-04T20:09:12", "published_display": "04 Jun 2026 20:09", "sentiment": "positive", "sentiment_pct": 65, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc Annual Shareholders Meeting Transcript", "summary": "This article provides the transcript for the 2026 Annual Shareholders Meeting of Myriad Genetics Inc. The meeting was called to order by Independent Chairman of the Board, S. Louise Phanstiel, at 8:00 AM Mountain Time, and an agenda for the meeting was made available on the compa", "url": "https://www.gurufocus.com/stock/MYGN/transcripts/8901765", "source_name": "GuruFocus", "published_at": "2026-06-04T14:09:12", "published_display": "04 Jun 2026 14:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Names Raj Jampa as New Chief Technology Officer", "summary": "Myriad Genetics, a leader in molecular diagnostic testing, has appointed Raj Jampa as its new Chief Technology Officer, effective June 1, 2026. Jampa will be responsible for technology strategy and execution, focusing on leveraging AI to enhance efficiency and customer experience", "url": "https://www.globenewswire.com/news-release/2026/06/02/3305286/0/en/myriad-genetics-names-raj-jampa-as-new-chief-technology-officer.html", "source_name": "GlobeNewswire", "published_at": "2026-06-03T04:09:12", "published_display": "03 Jun 2026 04:09", "sentiment": "positive", "sentiment_pct": 70, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) CTO Raj Jampa receives 251,889 restricted stock units", "summary": "Myriad Genetics' CTO, Raj Jampa, has been granted 251,889 restricted stock units (RSUs) as part of an equity compensation package. This award, which has no cash purchase price, vests in four equal annual installments starting one year from the grant date, aligning his compensatio", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-4-myriad-genetics-inc-insider-trading-activity-f27fef54494f.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:10:32", "published_display": "02 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) CTO Raj Jampa files initial Form 3 insider report", "summary": "Raj Jampa, Chief Technology Officer of Myriad Genetics (MYGN), has filed an initial Form 3 insider report. This filing establishes him as an insider for future reporting purposes but does not record any stock or option transactions, indicating a neutral impact on the company's st", "url": "https://www.stocktitan.net/sec-filings/MYGN/form-3-myriad-genetics-inc-initial-statement-of-beneficial-ownership-12cc8eb61922.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:10:32", "published_display": "02 Jun 2026 20:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Press Release: Myriad Genetics Names Raj Jampa as New Chief Technology Officer", "summary": "Myriad Genetics has announced the appointment of Raj Jampa as its new Chief Technology Officer (CTO). Jampa will be responsible for leading the company's technology strategy, including software development and bioinformatics infrastructure. This strategic hire aims to enhance Myr", "url": "https://www.moomoo.com/news/post/70934425/press-release-myriad-genetics-names-raj-jampa-as-new-chief?futusource=news_newspage_recommend", "source_name": "Moomoo", "published_at": "2026-06-02T15:10:32", "published_display": "02 Jun 2026 15:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics names Raj Jampa as chief technology officer", "summary": "Myriad Genetics, Inc. has appointed Raj Jampa as its new chief technology officer, effective Monday. Jampa will be responsible for leading the company's technology strategy, modernizing infrastructure, and scaling AI capabilities. His appointment is expected to help the molecular", "url": "https://www.investing.com/news/company-news/myriad-genetics-names-raj-jampa-as-chief-technology-officer-93CH-4722177", "source_name": "Investing.com", "published_at": "2026-06-02T13:40:19", "published_display": "02 Jun 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New CTO Raj Jampa to modernize tech and AI at Myriad Genetics", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQRFVhdDVqSDlLYndNbEpPMm5OQ05EbURhTmNiZHFEUklmZW1TX2pPX2EySHM1OFUwYXpSRkJyT2J5QThTVW1SbmdrbXVxNzZ0bEJHNVU4RFBfQkFMT0FSTnp4Qjl1cjM2bDFtWlpjMnNBZUpGZkoyVndyOFl2aW51dHVPSXMyNWFVZEd5SmZKdjBoOF9qRUN6UUJXMVZ2TnowU2xfckRIdmppZ0MxY2dV?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics, Inc. (MYGN) News, Articles, Events & Latest Updates", "summary": "This page provides the latest news and updates for Myriad Genetics, Inc. (MYGN), including stock performance, financial fundamentals, and recent articles. Key topics covered include the company's Q1 2026 earnings, upcoming product launches like the Prolaris + AI Test, analyst rat", "url": "https://stocktwits.com/symbol/MYGN/news", "source_name": "Stocktwits", "published_at": "2026-05-29T15:10:32", "published_display": "29 May 2026 15:10", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics' Upcoming Prolaris + AI Test Debut May Lift Its Stock", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/myriad-genetics-upcoming-prolaris-ai-132400644.html", "source_name": "Zacks", "published_at": "2026-05-28T13:24:00+00:00", "published_display": "28 May 2026 13:24", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Down 29.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Myriad (MYGN)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxPdFJpT2xJbnl6UlQ4aUNrS25wT2t0OVZ6Zm1XREI1TzNqcGtMUTVOYTFkSTFpVzlSdTd1RWlScnlsV1pYNTFRdEcwZF8tMXRaaGRndVlFQUk4YmQ3cUdqc2VOeC1lQ0tfLTNNeXlGRmlldjRiM196U0I5dUt2aUNTbnV1ZFFjMjVHVkE?oc=5", "source_name": "Market source", "published_at": "2026-05-18T07:00:00+00:00", "published_display": "18 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics stock (US62855J1043): Q1 2026 earnings miss and recent price drop", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQUEVjRGlnUk40NUZ4UmtudTY4TFVEXzAtWnFLa2V3UVJaUUEtMnBfWXFjV3VBUnkydUIyb1dMOUxZa3pNb18wdWJ5NGxLUk9lQ1pLOVluYXo2eUtIWlFPeUVUZzNsdWt3QS1fTFJOdF9WMHQ3dC1rZDJFNU1sODJZMXBNVTFtMnB2QjhJb2ZfMHZBa0ZwQW92dS04dm0tLUJlWkJwc05tQXQ5b0o2TnQ2Sm0yRWQwdS1FblBLSjMxeU1nb3BD?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Inc. (MYGN): Larry Robbins Likes This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPaWVwVVoxQnYxSGFFNVRCTlZGaW85N2FKQjRJd3ZnLTQwU0ttbXJPWjJVc3Y5OFJKOFVoUXdVakoyckpPWlljd3RYUkx2M2h5WWJRZ2hGTWRSTmZ0QjM2U2lsYVo2eDRYN3BBYXZnQ0xRVzZyVEVqN1YyQTJxeG9jRGtLdFlYYmk3RXdMeW1EUFNiMXlvbW15clpSX3BTS1Iw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics in record sell-off after Q1 miss", "summary": "", "url": "https://news.google.com/rss/articles/CBMiigFBVV95cUxOMXpsS2ZOdDc5RXhJMWxndWU2bk5YR1ZSQXc1dHowOVczR1g3eG4zS1RhU1ZVTlM4eHNNUTREbFJEbnVLTnRQV1NjNWtmQ3dMbmlHS1RxeS1kNEE4eDlVYk1rUHRKNGJCMm9lc1lvWFZqRnNucW90aTBsT1hhTW5fR0RRM3NKbVl6b1E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) Q1 Loss Of US$34.1 Million Reinforces Bearish Profitability Concerns", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxNa0R1d05KZE1qVlBnU2RQNUpRQUp4V0xibE13LTgwbkxsb052WXdyVV9US0FVTGxFdDdYaENMNVJpbHotX1diLXVIOG05VktyQnBHdXNJVkRzbVlyUHJJWnVNNkpfcERrNDBmZW4yTG80SG85TFlrV3piUDVfV1QtUW1LQnZEc0h3Nm5KRUNsT2VuYkZleE5lU181NFBpZ0dP?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) Reports Q1 Loss, Misses Revenue Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOUS1GdEV4WGdwdnFwZ3lZdmZLTnlDMDJqb1hjLWRVdlg5dk0wTzgzWDZfVm9wNnVQU190MVh1RnFFRVVqdTFqdDNsYjYtdGpVYk9BY0tYcEJ3a0RVYkljSmFER240THdKaC1uVkZ3NUh1bkFZZUxhUmdRUk96dzYzRllIMnluWjBrWUVxV19teWQyV2VGaE1xOURpdXo?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 18, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Small-Cap Stocks: Krispy Kreme, Myriad Genetics, and Hamilton Insurance Group to Avoid - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMic0FVX3lxTE9Damt6QjMzN2ZhYnBJS0JxU0ZzSGI1LXAwMmZ2aHo4T1pPbjBQZlZNdHVZX3BCZTBLOFdmek8xa3VkQnJVb3BVeHhrcEtEN09sdWYzUUZSSlRBVzhHSGlDQWtMSUlrSmdHdXhQXzF5bE1rSG8?oc=5", "source_name": "IndexBox", "published_at": "2026-04-26T07:00:00+00:00", "published_display": "26 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Q4 2025 Results: Revenue Beat, Raised Guidance - News and Statistics", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxOZzIyb0FCSGZNT1RzRnh4NG9LRzNWcFJoX0VwUE9OQkI5eE5BcVBlOGpSaUdic3hYd2ZzcWVSSVluamxhYzBXTC1NZGJkMHJhQUJMNDliTXc3QWplNjQyZngwXzNHUzFnZ2JncTRXOUw3Q0xvUVREbHdnVWlfOW5yN2RnaUxfWTBGTWRMdjE2R243allNWW1ISGJKd2M2c01YQWNv?oc=5", "source_name": "IndexBox", "published_at": "2026-04-07T07:00:00+00:00", "published_display": "07 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics And 2 Other Penny Stocks To Watch Closely", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxOTXNRMVpadDRYNDBTdHFQMDJYQkZDMGZ0NVNWX1h3N3JNR3Nnc3UxT202dmdyVGZKNlluV05ja2QxSmttTVVuUVA3SWtWNkNWZlZuNC1oVzlGWGxtVlAzcDZsdVhQUmxzZ2FFc0FIT19GMk9NMWFpS1hnR3YtWTZvb090WlNXZ2YxUW5XQUpWN0VZbU5RdFFXOVZ3?oc=5", "source_name": "Market source", "published_at": "2026-04-06T07:00:00+00:00", "published_display": "06 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) Stock Trades Up, Here Is Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxNUXM4OFZEczV5ZHNlc1pEN0lJNGlDa1F4NjN0MWFydWFvcU9GQ2R5WXQzRjRPaV9pRFh6WnNyX05lVHdETlE4VXAzSy01TEg4U3gwWERaQTRaR1ctd2ZUb1hSQ2hzbElQYVQyNjBISTVJeFI3cVVxSUJ0REF4bzZDQ3h3c2cydw?oc=5", "source_name": "Market source", "published_at": "2026-03-03T08:00:00+00:00", "published_display": "03 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics (MYGN) Stock Falls on Q4 2025 Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMilgFBVV95cUxOZE5GNWRZUERzNlEzZkN1WERnMWk5VTkwS1NGTWxYV2JXWW84QlJXWlpndkw4SzVrMjktVVpWYm52LUlNV1dPWjRuak0wUXJJcWxmVUkzZFE0b04xXzd1LUZHRnVKak9vRFRBbkZfUjBIS205X3JzZF9kNHFfQjRfTHBGMnBHWW5LTUtYaHdPVGZmMzNTb1E?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-02-23T08:00:00+00:00", "published_display": "23 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 22, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Little Excitement Around Myriad Genetics, Inc.'s (NASDAQ:MYGN) Revenues As Shares Take 27% Pounding", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Analysts See The Myriad Genetics (MYGN) Story Shifting After The New $7 Target", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxPMFMwTmN3VkxnZW9KOHZwSEtlaXhWYmxiSUVQUFVyWHhnOFI2RHU1Tkh6SC1qaFZDanZtMUVaRl8wbHdKdG1DYlpxS3N5ajdPS1AydXUwbEdtcFhOcmlNNGJ0QWNQdURiQmozeFdtcUdra1ZMd2h6dFFDcDRlNVR1NS1fYTg?oc=5", "source_name": "Market source", "published_at": "2026-02-05T08:00:00+00:00", "published_display": "05 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Does Myriad Genetics (NASDAQ:MYGN) Have A Healthy Balance Sheet?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-04T08:00:00+00:00", "published_display": "04 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxQZktGM0tUVjlYN3pQczJDS29wREgxWTRnQ1daT2xoN2ZPOFI0VDZsTEo3LUVINi0zaXlOR25OM0pQOHh4Nk1jNjY1dDQzUVNMX0d0a21IVnhINDFMV2NLRnEyWjFST0x1TTRndWpDQ0l6ZVVfZ2VycWlYTjJIUV94dzFQSV9oUHMtSDd2eGt2SEY5M3VM?oc=5", "source_name": "Market source", "published_at": "2026-01-12T08:00:00+00:00", "published_display": "12 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Myriad Genetics (MYGN) Stock Is Down Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMiggFBVV95cUxNdFR3YkJLaEFsM3JuQmFKR0ExN09BTUdwWml5ZWxBdU5yV3lIVTk4RG5vYjlzVnFsdlItTUdhSzZaeUJjUElKMXktV1ZKNGs0a0I5LUhzLW9MSHhYWkwxUGczcWFESkt3azU2bmZ3NGswU19aN3laTDh1cllHVmVnaG1n?oc=5", "source_name": "Market source", "published_at": "2025-11-04T08:00:00+00:00", "published_display": "04 Nov 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 100, "total_relevant": 45, "sentiment_summary": {"positive": 10, "negative": 6, "neutral": 29, "score": 52, "total": 45, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 83, "events": [{"event": "general", "label": "Market update", "weight": 16.65, "count": 29}, {"event": "earnings", "label": "Earnings", "weight": 4.95, "count": 9}, {"event": "liquidity", "label": "Balance sheet", "weight": 2.2, "count": 4}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 10, "negative_events": 6}, "market_context": {"has_market_context": true, "latest_close": 4.54, "latest_week": "2026-06-19", "one_week_move": 4.8, "four_week_move": 18.8, "twelve_week_move": 6.1, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.385012, "market_dynamics_buy_signal": false, "relative_strength": -34.87077, "fair_value_gap": -67.4, "fair_value_label": "Below fair value", "fair_value_tone": "positive", "expectation_direction": "negative", "expectation_probability": 44.0014, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+4.8% over one week, +18.8% over four weeks, trend inactive, and below fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 61, "badges": ["Value support"], "opportunities": ["Price is below fair value while news tone is not negative."], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 15}, {"label": "Market source", "count": 10}, {"label": "TradingKey", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "IndexBox", "count": 2}, {"label": "Yahoo! Finance Canada", "count": 1}, {"label": "MarketBeat", "count": 1}, {"label": "GuruFocus", "count": 1}], "tiers": [{"label": "Direct company coverage", "count": 45}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 29}, {"label": "Earnings", "count": 9}, {"label": "Balance sheet", "count": 4}, {"label": "Capital return", "count": 1}, {"label": "Guidance", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "52/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "83/100 classification confidence."}, {"label": "Company focus", "value": "45", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "2", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "+4.8% over one week, +18.8% over four weeks, trend inactive, and below fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Myriad Genetics Inc (MYGN) Dividends & Stock Splits: Historical Payouts and Event Timeline"}], "updated_at": "2026-06-23T06:06:06.891336+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}